why choose us

First received: June 05, 2023

Clinical Trial: JSP191 (Briquilimab) in Subjects With LR-MDS

Study Status: Completed

Recruit Status: RECRUITING

Condition: Lower-risk Myelodysplastic Syndrome

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Open-label, Dose-escalation, Safety, and Tolerability Study of JSP191 as a Second-line Therapy in Subjects With Lower-Risk Myelodysplastic Syndrome (LR-MDS)

Brief Summary: A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.

Read more